Takeda Oncology | Leading Cancer Treatment Innovation

A person in a lab coat holding a pipette

Decades of Leadership in Oncology

ABOUT TAKEDA ONCOLOGY

Recent Oncology News

Takeda to Present New Data Highlighting Patient Centered Research in Hematologic, Thoracic and Gastrointestinal Cancers at the 2026 ASCO Annual Meeting

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 5, 2026

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

December 6, 2025

At Takeda, we aspire to cure cancer, with inspiration from patients and innovation from everywhere.

Better Health, Brighter Future

Our Medicines

We're committed to advancing treatment options that enhance & extend the lives of people living with cancer.

Oncology Pipeline

Our R&D efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers.

Patient Advocacy & Support

We're committed to helping people living with cancer navigate their journey – from diagnosis to survivorship.

Connect with Us

Contact Takeda Oncology for resources, information, or support.